Table 2.
Anti-inflammatory effect of C. chayamansa extract and primary fractions F14-42 on the TPA model.
| Treatment 1 | Dose (mg/kg) |
T(6h) | Inhibition percentage (%) | ED50 (mg/kg) |
|
| ||||
| TPA | - | 20.60±0.64 | --- | --- |
| 0.5 | 16.92±0.38a | 17.88% | ||
| IND | 1 | 14.07±0.40•a | 41.77% | 2.14 |
| 2 | 10.77±0.34•∗a | 47.73% | ||
|
| ||||
| CnCM | 0.5 | 17.43±0.33a | 15.37% | 1.58 |
| 1 | 11.48±0.57•ab | 44.26% | ||
| 2 | 9.45±0.98•∗ab | 54.13% | ||
|
| ||||
| Treatment 2 | ||||
|
| ||||
| IND | 0.5 | 8.62±0.23∗ | 45.64% | 1.28 |
| 1 | 7.9±0.44∗ | 50.18% | ||
| 2 | 5.68±0.38∗abd | 64.18% | ||
|
| ||||
| Primary fraction 14-42 | 0.5 | 9.42±0.56∗ | 15.37% | 1.48 (R2=0.99) |
| 1 | 8.58±0.64∗ | 44.26% | ||
| 2 | 7.46±0.46∗b | 54.13% | ||
Data shown as mean (±), with standard error of the mean (SEM). Statistical analysis two-way ANOVA and post hoc SNK test (p ≤0.05). Treatment 1: avs TPA control, bvs IND, cvs CnCM 0.5 mg/ear, and dvs CnCM 1 mg/ear. Treatment 2: ∗vs TPA control, avs IND 0.5 mg/ear, bvs IND 1 mg/ear, cvs fractions 14-42 0.5 mg/ear, and dvs fractions 14-42 1 mg/ear; CnCM: extract CHCl3:MeOH; IND: Indomethacin; n = 6.